Borazanci EH et al. A phase II pilot trial of nivolumab + albumin bound paclitaxel + paricalcitol + cisplatin + gemcitabine (NAPPCG) in patients with previously untreated metastatic pancreatic ductal adenocarcinoma. Gastrointestinal Cancers Symposium 2018;Abstract 358.
Carnevale J, Ashworth A. Assessing the significance of BRCA1 and BRCA2 mutations in pancreatic cancer. J Clin Oncol 2015;33(28):3080-1. Abstract
Chiorean EG et al. Performance status dynamics during treatment with nab-paclitaxel plus gemcitabine versus gemcitabine alone for metastatic pancreatic cancer. Cancer Manag Res 2018;10:1389-96. Abstract
Chiorean EG et al. Real-world comparative effectiveness of nab-paclitaxel plus gemcitabine (nab-P/G) vs FOLFIRINOX (FFX) in patients (pts) with advanced pancreatic cancer (aPC). Proc ESMO 2018;Abstract 724P.
Chiorean EG et al. A phase II study of abemaciclib as a monotherapy and in combination with other agents in patients with previously treated metastatic pancreatic ductal adenocarcinoma (PDAC). Proc ASCO 2017;Abstract TPS4150.
Chiorean EG et al. Randomized phase II study of 2nd-line FOLFIRI versus modified FOLFIRI with PARP inhibitor ABT-888 (veliparib) (NSC-737664) in metastatic pancreatic cancer (mPC): SWOG S1513. Proc ASCO 2017;Abstract TPS4147.
Doherty GJ et al. HALO-109-301: A phase III trial of PEGPH20 (with gemcitabine and nab-paclitaxel) in hyaluronic acid-high stage IV pancreatic cancer. Future Oncol 2018;14(1):13-22. Abstract
Goldstein D et al. Nomogram for predicting overall survival (OS) in patients (pts) treated with nab-paclitaxel (nab-P) plus gemcitabine (Gem) or Gem alone for metastatic pancreatic cancer (MPC). Proc ASCO 2017;Abstract 4109.
Hingorani SR et al. HALO 202: Randomized phase II study of PEGPH20 plus nab-paclitaxel/gemcitabine versus nab-paclitaxel/gemcitabine in patients with untreated, metastatic pancreatic ductal adenocarcinoma. J Clin Oncol 2018;36(4):359-66. Abstract
Neoptolemos JP et al. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): A multicentre, open-label, randomised, phase 3 trial. Lancet 2017;389(10073):1011-24. Abstract
Ouyang G et al. Gemcitabine plus cisplatin versus gemcitabine alone in the treatment of pancreatic cancer: A meta-analysis. World J Surg Oncol 2016;14:59. Abstract
Picozzi VJ et al. Initial gemcitabine/nab-paclitaxel (GA) followed by sequential (S) mFOLFIRINOX or alternating (A) mFOLFIRI in metastatic pancreatic cancer (mPC): The SEENA-1 study. Gastrointestinal Cancers Symposium 2017;Abstract 359.
Ramanathan RK et al. A phase IB/II randomized study of mFOLFIRINOX (mFFOX) + pegylated recombinant human hyaluronidase (PEGPH20) versus mFFOX alone in patients with good performance status metastatic pancreatic adenocarcinoma (mPC): SWOG S1313 (NCT#01959139). Gastrointestinal Cancers Symposium 2018;Abstract 208.
Ramanathan RK et al. Correlation between ferumoxytol uptake in tumor lesions by MRI and response to nanoliposomal irinotecan in patients with advanced solid tumors: A pilot study. Clin Cancer Res 2017;23(14):3638-48. Abstract
S1313, a phase IB/II randomized study of modified FOLFIRINOX + pegylated recombinant human hyaluronidase (PEGPH20) versus modified FOLFIRINOX alone in patients with good performance status metastatic pancreatic adenocarcinoma. NCT01959139
Sohal D et al. SWOG S1505: A randomized phase II study of perioperative mFOLFIRINOX vs gemcitabine/nab-paclitaxel as therapy for resectable pancreatic adenocarcinoma. Proc ASCO 2017;Abstract TPS4152.
Sonbol MB et al. Second-line treatment in patients with pancreatic ductal adenocarcinoma: A meta-analysis. Cancer 2017;123(23):4680-6. Abstract
Suker M et al. FOLFIRINOX for locally advanced pancreatic cancer: A systematic review and patient-level meta-analysis. Lancet Oncol 2016;17(6):801-10. Abstract
Wang-Gillam A et al. NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: Final overall survival analysis and characteristics of long-term survivors. Eur J Cancer 2019;[Epub ahead of print]. Abstract
Zhen DB et al. Biomarker-driven and molecularly targeted therapies for pancreatic adenocarcinoma. Semin Oncol 2018;45(3):107-15. Abstract